Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 3107

Next Previous
Search
Drug Profile

INO 3107

Alternative Names: INO-3106; INO-3107

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; University of Pennsylvania
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Recurrent respiratory papillomatosis
  • Discontinued Head and neck cancer; Human papillomavirus infections; Lung cancer

Most Recent Events

  • 12 Feb 2025 INOVIO Pharmaceuticals plans to submit a Biologics license application (BLA) in Recurrent Respiratory Papillomatosis via FDA's accelerated approval program in USA, in mid 2025
  • 12 Feb 2025 Updated safety, efficacy and immunogenicity data from a phase I/II trial for Recurrent respiratory papillomatosis released by INOVIO
  • 09 Jan 2025 Inovio Pharmaceuticals plans to submit a redosing study protocol to the US FDA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top